News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Janssen Research & Development and Johnson & Johnson (JNJ) to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)


5/3/2013 7:29:00 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW BRUNSWICK, N.J., May 2, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Friday, May 3, at approximately 8:30 a.m., Eastern Time, to discuss simeprevir phase 3 clinical data presented at The International Liver Congress of the European Association for the Study of the Liver (EASL).

A pre-recorded webcast featuring management from Janssen will provide an overview of results from the phase 3 QUEST -1 and QUEST-2 studies of the investigational protease inhibitor simeprevir (TMC435) administered once daily in combination with pegylated interferon and ribavirin in treatment-naive genotype 1 chronic hepatitis C patients.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations."

SOURCE Johnson & Johnson

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES